Barclays’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-38,900
| Closed | -$3.69M | – | 6276 |
|
|
2020
Q1 | $3.69M | Buy |
38,900
+35,500
| +1,044% | +$3.37M | ﹤0.01% | 1727 |
|
|
2019
Q4 | $299K | Sell |
3,400
-4,000
| -54% | -$352K | ﹤0.01% | 4732 |
|
|
2019
Q3 | $590K | Buy |
7,400
+2,900
| +64% | +$234K | ﹤0.01% | 4111 |
|
|
2019
Q2 | $351K | Sell |
4,500
-29,300
| -87% | -$2.74M | ﹤0.01% | 4637 |
|
|
2019
Q1 | $3.97M | Buy |
33,800
+32,700
| +2,973% | +$3.81M | ﹤0.01% | 1859 |
|
|
2018
Q4 | $120K | Sell |
1,100
-1,100
| -50% | -$128K | ﹤0.01% | 4921 |
|
|
2018
Q3 | $281K | Buy |
2,200
+700
| +47% | +$86.6K | ﹤0.01% | 4729 |
|
|
2018
Q2 | $170K | Sell |
1,500
-800
| -35% | -$87.9K | ﹤0.01% | 4854 |
|
|
2018
Q1 | $258K | Sell |
2,300
-5,300
| -70% | -$673K | ﹤0.01% | 4600 |
|
|
2017
Q4 | $1.12M | Buy |
7,600
+2,300
| +43% | +$292K | ﹤0.01% | 3006 |
|
|
2017
Q3 | $621K | Buy |
5,300
+4,000
| +308% | +$511K | ﹤0.01% | 3413 |
|
|
2017
Q2 | $169K | Sell |
1,300
-61,300
| -98% | -$7.65M | ﹤0.01% | 4514 |
|
|
2017
Q1 | $8.47M | Buy |
62,600
+54,000
| +628% | +$8.18M | 0.01% | 982 |
|
|
2016
Q4 | $1.23M | Buy |
8,600
+500
| +6% | +$63.8K | ﹤0.01% | 2551 |
|
|
2016
Q3 | $956K | Sell |
8,100
-57,600
| -88% | -$6.92M | ﹤0.01% | 2667 |
|
|
2016
Q2 | $6.96M | Buy |
65,700
+12,300
| +23% | +$1.37M | 0.01% | 1080 |
|
|
2016
Q1 | $5.93M | Buy |
53,400
+50,900
| +2,036% | +$6.44M | 0.01% | 1061 |
|
|
2015
Q4 | $390K | Sell |
2,500
-1,100
| -31% | -$160K | ﹤0.01% | 3386 |
|
|
2015
Q3 | $472K | Sell |
3,600
-1,800
| -33% | -$289K | ﹤0.01% | 3390 |
|
|
2015
Q2 | $934K | Sell |
5,400
-14,400
| -73% | -$2.59M | ﹤0.01% | 2935 |
|
|
2015
Q1 | $3.41M | Buy |
19,800
+7,300
| +58% | +$1.11M | ﹤0.01% | 1866 |
|
|
2014
Q4 | $1.61M | Sell |
12,500
-5,600
| -31% | -$722K | ﹤0.01% | 2723 |
|
|
2014
Q3 | $2.32M | Buy |
18,100
+5,300
| +41% | +$546K | ﹤0.01% | 2529 |
|
|
2014
Q2 | $1.13M | Buy |
12,800
+10,300
| +412% | +$991K | ﹤0.01% | 3217 |
|
|
2014
Q1 | $235K | Buy |
2,500
+400
| +19% | +$40.9K | ﹤0.01% | 4630 |
|
|
2013
Q4 | $237K | Sell |
2,100
-4,900
| -70% | -$442K | ﹤0.01% | 4847 |
|
|
2013
Q3 | $546K | Sell |
7,000
-59,700
| -90% | -$4.36M | ﹤0.01% | 4017 |
|
|
2013
Q2 | $4.39M | Buy |
+66,700
| New | +$4.3M | 0.01% | 1728 |
|
Other funds holding UTHR
ACA
JT
Barclays's UTHR Position: Q2 2026 in Review
Barclays increased its United Therapeutics (UTHR) stake by 14% in Q2 2026, buying an estimated $5.07M and bringing the position to 72,010 shares worth $39M. The position accounts for 0.01% of the portfolio, ranked #837.
Barclays first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $47.3M in Q3 2025. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Barclays held 72,010 shares of United Therapeutics worth $39M as of Q2 2026.
- Barclays bought 9,005 United Therapeutics shares in Q2 2026, an estimated $5.07M.
- United Therapeutics made up 0.01% of Barclays's portfolio in Q2 2026, its #837 holding.
- Barclays first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Barclays's United Therapeutics position peaked at $47.3M in Q3 2025.
- 881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.